Sino Biopharmaceutical Limited (OTCMKTS:SBMFF) Short Interest Up 418.8% in September

Sino Biopharmaceutical Limited (OTCMKTS:SBMFF - Get Free Report) was the target of a significant increase in short interest in the month of September. As of September 30th, there was short interest totalling 140,600 shares, an increase of 418.8% from the September 15th total of 27,100 shares. Based on an average daily trading volume, of 1,700 shares, the short-interest ratio is presently 82.7 days.

Sino Biopharmaceutical Stock Performance

OTCMKTS:SBMFF remained flat at $0.47 during trading hours on Thursday. The firm has a 50 day simple moving average of $0.40 and a 200 day simple moving average of $0.36. Sino Biopharmaceutical has a one year low of $0.31 and a one year high of $0.49.

Sino Biopharmaceutical Company Profile

Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, pomalidomide capsules under Anyue brand, bevacizumab injection under Anbeisi brand, rituximab injection under Delituo brand, and trastuzumab for injection under Saituo brand; liver disease medications, such as magnesium isoglycyrrhizinate injection under Tianqing Ganmei brand and entecavir dispersible tablets under Runzhong brand; and respiratory system medicines comprising budesonide suspension for inhalation under Tianqing suchang brand and colistimethate sodium for injection under Tianyun brand.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.